mohd izzuan 10x Genomics ( NASDAQ: TXG ) shares are down ~7% in after-hours trading Tuesday after lowering its 2024 revenue guidance range. The company is now projecting full-year revenue of $595M to $605M compared to $640M to $660M previously. The updated range is a 3% decrease from the full.
